Stydy of DE-766 in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Phase 3

• Conditions: nresectable Locally Advanced Squamous Cell Lung Cancer

• Registration Number: JPRN-jRCT2080222038
• Lead Sponsor: DAIICHISANKYO Co.,Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 420

Inclusion Criteria

1) Patients with stage IIIA or IIIB of squamous cell lung cancer
2) Patients with unresectable squamous cell lung cancer
3) Patients who are judged suitable for radical radiotherapy
4) Patients who have received no prior treatment for lung cancer

Exclusion Criteria

1) Patients with contralateral hilar lymph node metastasis
2) Patients with obvious pulmonary fibrosis or interstitial pneumonitis on chest CT scans
3) Patients with a severe pulmonary disease such as intense pulmonary emphysema, serious chronic bronchitis, or serious bronchial asthma
4) Patients with severe infection
5) Patients with severe cardiovascular disease
6) Patients with uncontrolled diabetes mellitus
7) Patients with another active malignancy
8) Patients with a history of prior radiotherapy to chest
9) Patients who have received with any EGFR targeted drug at any time
10) Patients who received another investigational drug within 4 weeks prior to randomization.

Study & Design

• Study Type: Interventional
• Study Design: Not specified